News | November 24, 2014

Fat Around the Heart May Cause AFib According to Loyola Study

Findings show that fat layers may be a better predictor than BMI

AFIB, BMI, Loyola University Medical Center, Epicardial Adipose Tissue

November 24, 2014 — Obesity is a known risk factor for atrial fibrillation (AFib), the most common heart rhythm disorder.

Obesity is commonly measured as a person’s body mass index (BMI), but a Loyola University Medical Center study has found that the layer of fat around the outside of the heart is more closely associated with atrial fibrillation than BMI.

“Many people who would not be considered obese by their BMI have high volumes of fat around their hearts, which could put them at risk for atrial fibrillation. Simple measures such as BMI may fail to completely inform us of a patient’s true cardiovascular risk,” says Mark Rabbat, M.D., first author of the study and an assistant professor of medicine and radiology, Division of Cardiology, at Loyola University Medical Center.

The study found a statistically significant correlation between the fat layer and scarring in the left atrium that causes atrial fibrillation. By contrast, there was not a statistically significant correlation between BMI and scarring in the left atrium of the heart.

AFib, occurs when the atria fibrillate. AFib is thought to be caused by inflammation and scarring (fibrosis) in the left atrium.

New innovations in cardiac magnetic resonance imaging enable physicians to precisely measure both epicardial adipose tissue (EAT) volume and the amount of fibrosis in the left atrium.

The study included 54 patients who had AFib. The average amount of fat around the heart (EAT volume) was 120 cubic centimeters. There was a statistically significant correlation of 0.45 between EAT volume and fibrosis. By comparison, there was only a 0.30 correlation between BMI and fibrosis – and this lower correlation was not statistically significant.

For many years, EAT was believed to be harmless, inert fat tissue, but it now appears that EAT is a metabolically active organ, releasing proteins that may trigger the fibrosis that causes AFib.

Weight loss, either through diet and exercise or through weight-loss surgery, has been shown to reduce the amount of EAT, but current medical treatments fail to specifically target EAT.

Rabbat remarks: “Fat tissue around the heart may be a novel target to reduce the risk of a-fib and its recurrence.”

The study is titled "Epicardial adipose tissue volume predicts extent of left atrial fibrosis in patients with atrial fibrillation."

Other co-authors of the study, all at Loyola, are Bassel Sayegh, M.D.; Andrew Stiff, M.D.; Brian Vetter, MS; Kim Chan, MBBS; Tonye Teme, M.D. and senior author David Wilber, M.D.

For more information: www.loyolamedicine.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now